144 related articles for article (PubMed ID: 28475329)
1. Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.
Tabata H; Yoneda T; Oshitari T; Takahashi H; Natsugari H
J Med Chem; 2017 May; 60(10):4503-4509. PubMed ID: 28475329
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Characterization of New V
Szeleczky Z; Szakács Z; Bozó É; Baska F; Vukics K; Lévai S; Temesvári K; Vass E; Béni Z; Krámos B; Magdó I; Szántay C; Kóti J; Domány-Kovács K; Greiner I; Bata I
J Med Chem; 2021 Jul; 64(14):10445-10468. PubMed ID: 34255509
[TBL] [Abstract][Full Text] [Related]
3. Atropisomerism in the vaptan class of vasopressin receptor ligands: the active conformation recognized by the receptor.
Tabata H; Nakagomi J; Morizono D; Oshitari T; Takahashi H; Natsugari H
Angew Chem Int Ed Engl; 2011 Mar; 50(13):3075-9. PubMed ID: 21404400
[No Abstract] [Full Text] [Related]
4. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
[TBL] [Abstract][Full Text] [Related]
5. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
[TBL] [Abstract][Full Text] [Related]
6. [Management of ascites in cirrhotic patients].
Kurosaki M; Nakanishi H; Izumi N
Nihon Shokakibyo Gakkai Zasshi; 2017; 114(1):27-34. PubMed ID: 28070092
[No Abstract] [Full Text] [Related]
7. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
Rangasetty UC; Gheorghiade M; Uretsky BF; Orlandi C; Barbagelata A
Expert Opin Investig Drugs; 2006 May; 15(5):533-40. PubMed ID: 16634691
[TBL] [Abstract][Full Text] [Related]
8. N-benzoyl-1,5-benzothiazepine and its S-oxide as vasopressin receptor ligands: insight into the active stereochemistry around the seven-membered ring.
Yoneda T; Tabata H; Tasaka T; Oshitari T; Takahashi H; Natsugari H
J Med Chem; 2015 Apr; 58(7):3268-73. PubMed ID: 25774991
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V
Ali Y; Dohi K; Okamoto R; Katayama K; Ito M
Br J Pharmacol; 2019 May; 176(9):1315-1327. PubMed ID: 30801659
[TBL] [Abstract][Full Text] [Related]
10. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice.
Zeynalov E; Jones SM; Seo JW; Snell LD; Elliott JP
PLoS One; 2015; 10(8):e0136121. PubMed ID: 26275173
[TBL] [Abstract][Full Text] [Related]
11. Review of tolvaptan for autosomal dominant polycystic kidney disease.
Baur BP; Meaney CJ
Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
[TBL] [Abstract][Full Text] [Related]
12. A Three-Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors.
Saleh N; Saladino G; Gervasio FL; Haensele E; Banting L; Whitley DC; Sopkova-de Oliveira Santos J; Bureau R; Clark T
Angew Chem Int Ed Engl; 2016 Jul; 55(28):8008-12. PubMed ID: 27184628
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
Nakanishi H; Kurosaki M; Hosokawa T; Takahashi Y; Itakura J; Suzuki S; Yasui Y; Tamaki N; Nakakuki N; Takada H; Higuchi M; Komiyama Y; Yoshida T; Takaura K; Hayashi T; Kuwabara K; Sasaki S; Izumi N
J Gastroenterol; 2016 Jun; 51(6):620-7. PubMed ID: 26610908
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).
Ślusarz MJ
Expert Opin Ther Pat; 2015 Jun; 25(6):711-22. PubMed ID: 25776143
[TBL] [Abstract][Full Text] [Related]
15. Ligand recognition properties of the vasopressin V2 receptor studied under QSAR and molecular modeling strategies.
Martínez-Archundia M; Colín-Astudillo B; Moreno-Vargas LM; Ramírez-Galicia G; Garduño-Juárez R; Deeb O; Contreras-Romo MC; Quintanar-Stephano A; Abarca-Rojano E; Correa-Basurto J
Chem Biol Drug Des; 2017 Nov; 90(5):840-853. PubMed ID: 28419717
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
Burrell LM; Risvanis J; Johnston CI; Naitoh M; Balding LC
Exp Physiol; 2000 Mar; 85 Spec No():259S-265S. PubMed ID: 10795930
[TBL] [Abstract][Full Text] [Related]
17. Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus.
Kang SW; Jayanthi S; Nagarajan G; Suresh Kumar TK; Kuenzel WJ
J Biomol Struct Dyn; 2019 Apr; 37(7):1685-1699. PubMed ID: 29658387
[TBL] [Abstract][Full Text] [Related]
18. Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
Ikeda T; Iwanaga Y; Watanabe H; Morooka H; Akahoshi Y; Fujiki H; Miyazaki S
J Cardiovasc Pharmacol; 2015 Nov; 66(5):487-96. PubMed ID: 26248278
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
[TBL] [Abstract][Full Text] [Related]
20. New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.
Bozó É; Baska F; Lövei K; Szántó G; Domány-Kovács K; Kurkó D; Szondiné Kordás K; Szokoli T; Bata I
Bioorg Med Chem Lett; 2020 Sep; 30(18):127417. PubMed ID: 32731087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
